The genetic telemedicine services provider doubled its total funding to $46m in a round featuring Echo Health Ventures, GE, Illumina, Kaiser Permanente and Manatt, Phelps & Phillips.

Erganeo is the new moniker for regional tech transfer office Satt IDF Innov, which has invested $30.5m over the past seven years and is adopting an increasingly deep tech-led focus.

Cancer therapy developer ADC has attracted $76m to extend its series E round, after AstraZeneca supported a $200m initial tranche in 2017.

Merck & Co will pay up to $773m to acquire biopharmaceutical developer Tilos Therapeutics, based on research at Harvard Medical School and Brigham & Women’s Hospital.

Merck & Co will pay up to $773m to acquire biopharmaceutical developer Tilos Therapeutics providing exits to co-founders Boehringer Ingelheim and Partners HealthCare.

Cancer drug developer Oncologie raised $80m from investors including Nan Fung Life Sciences and the Nan Fung-funded Pivotal BioVentures China.

Artizan, a Yale University spinout focused on intestinal microbiota targets potentially responsible for inflammatory bowel disease, has been backed by investors including Brii Biosciences, bringing its total funding to $12m.

Third Rock’s fifth vehicle will bid to form and invest in more promising biotech ventures to follow the likes of multiple spinouts, such as Johns Hopkins' Thrive Earlier Detection.

Each Friday the Global Corporate Venturing Deal Net rounds up the week’s smaller deals and tracks the emerging companies accessing corporate funds.

University of Buffalo and Buffalo Niagara Medical Science have cut the ribbon on a new $32m innovation program aimed at commercialising local medical research.